Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02527122
Other study ID # MM09-STD-011
Secondary ID 2013-005394-45
Status Completed
Phase N/A
First received
Last updated
Start date July 21, 2016
Est. completion date August 2018

Study information

Verified date August 2018
Source Inmunotek S.L.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Four concentrations of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm..


Description:

This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 2018
Est. primary completion date July 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Clinical history positive inhalation allergy (rhinitis I rhinoconjunctivitis I asthma) against Dermatophagoides pteronyssinus or Dermatophagoides farinae.

- A prick-test positive (average of the papule = 3 mm diameter) with a summary of the same allergen I presence against the allergen specific Immunoglobulin E.

- The average area of the papule obtained by histamine dihydrochloride to 10 mgml must be greater than or equal 7 mm2.

- Age: over 18 years of age.

- Both sexes.

Exclusion Criteria:

- Subjects outside of the age range.

- Individuals who have previously received immunotherapy in the last 5 years for the treatment of asthma or the allergic rhinoconjunctivitis induced by allergens that may interfere with the extract mixture of Dermatophagoides pteronyssinus or farinae.

- Subjects with important symptoms of rhinoconjunctivitis I bronchial asthma in which the suspension of the antihistamine treatment for systemic is contraindicated.

- Subjects that have previously submitted a serious secondary reaction during skin prick test diagnostic tests.

- Subjects in treatment with ss-blockers.

- Unstable subjects of clinical point of view (asthma acute, febrile, etc.).

- Subjects with lesions of active hives, severe active dermographism, severe atopic dermatitis, sunburn, eczema, lesions of psoriasis in the area of realization of the prick test (risk of false positives).

- Subjects with viral infection activates the herpes simplex or herpes varicella-zoster in the area of realization of the prick test.

- Subjects that have some pathology in which the administration of adrenaline (hyperthyroidism, hypertension, heart disease, etc.) is contraindicated.

- States of the subject that can not offer cooperation and severe psychiatric disorders.

- Pregnant or women at risk of pregnancy and breastfeeding women.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Allergen extracts


Locations

Country Name City State
Spain Hospital Univ. Ntra. Sra. de la Candelaria Sta. Cruz de Tenerife Islas Canarias

Sponsors (1)

Lead Sponsor Collaborator
Inmunotek S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The wheal size diameter on the skin at the site of the puncture during the immediate phase when applied each concentration of the allergen extract wheal size diameter OF THE SKIN PRICK TEST 1 hour
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02527187 - Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa Phase 2
Completed NCT01441076 - Anakinra for Behcet s Disease Phase 1/Phase 2
Completed NCT01472263 - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Phase 3
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Suspended NCT04642066 - Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Completed NCT04103099 - Impact of HLNatural Immune Supplement on Colds N/A
Recruiting NCT03344094 - Mechanism of Action of Ocrelizumab in Multiple Sclerosis N/A
Active, not recruiting NCT05445284 - Group Education Trial to Improve Transition for Parents of Adolescents With T1D N/A
Recruiting NCT06104111 - Epigenetic Memory of Vitamin D Supplementation Phase 1
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Completed NCT01510626 - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center Phase 1
Completed NCT01490177 - Single Center Food Allergy Oral Immunotherapy Study Phase 1
Completed NCT03922087 - No-worry Baby Project